nChroma Bio
nChroma Bio is a clinical-stage genetic medicines company developing in vivo epigenetic editing therapies for chronic hepatitis B, cardiometabolic, and CNS indications using lipid nanoparticle and engineered virus-like particle delivery platforms.
- Company typePrivate
- Founded2024
- HeadquartersBoston, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What nChroma Bio does
nChroma Bio is a clinical-stage genetic medicines company developing in vivo therapies that combine epigenetic editing cargoes with targeted delivery systems to treat diseases of high unmet need. The company applies a disease-first approach, pairing specific genetic payloads with delivery technologies tailored to the biological context of each indication. Its primary therapeutic focus is chronic hepatitis B, with additional programs in cardiometabolic disease (PCSK9) and central nervous system disorders.
The company's technology platform rests on two pillars. First, an epigenetic editing cargo system that regulates gene expression through DNA methylation and chromatin modifications without cutting or nicking the genome, eliminating the DNA-damage risk associated with conventional CRISPR/Cas9 editing. Second, a modular delivery suite comprising lipid nanoparticles (LNPs) for liver-directed applications and engineered virus-like particles (eVLPs, branded DLVR) for extrahepatic tissues. The lead clinical candidate, CRMA-1001, is a liver-directed epigenetic silencer delivered via LNP and is being evaluated in an open-label Phase 1/2 trial (NCT07200193) for potential functional cure of chronic hepatitis B and HBV/HDV coinfection. Additional pipeline programs include a PCSK9 epigenetic editor and a multiplex epi/gene editing program in cardiometabolic disease, plus research-stage CNS programs using next-generation compact epigenetic editors.
The company is privately held and pre-revenue, generating no commercial sales. Its economic model depends on advancing internal pipeline assets through clinical milestones and executing strategic partnerships or licensing arrangements with larger pharmaceutical and biotech companies for both pipeline assets and platform technologies. nChroma was formed on December 11, 2024 through the merger of Chroma Medicine and Nvelop Therapeutics, with a $75 million oversubscribed financing completed concurrently, providing multiple years of runway to drive CRMA-1001 through clinical readouts and build the broader pipeline. The first patient was dosed in January 2026 across sites in Hong Kong, New Zealand, and the United Kingdom.
nChroma Bio firmographics
Firmographics- Name
- nChroma Bio
- Legal name
- nChroma Bio, Inc.
- Website
- https://nchromabio.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- nChroma Bio is a clinical-stage genetic medicines company developing in vivo epigenetic editing therapies for chronic hepatitis B, cardiometabolic, and CNS indications using lipid nanoparticle and engineered virus-like particle delivery platforms.
- Ownership category
- akta.pro rank
nChroma Bio industry classification
Industry- Product category
- Genetic Medicines / Epigenetic Editing Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro industry
- Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods)
Keywords
Where nChroma Bio is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Markets served
nChroma Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pre-Revenue / Clinical-Stage: nChroma Bio is a clinical-stage genetic medicines company that is pre-commercial and pre-revenue. Revenue generation strategy is expected to rely on strategic partnerships, licensing of platform technologies, and future commercialization through partnerships given the company's pipeline stage.
- Strategic Partnership Potential: Modular delivery solutions and diverse therapeutic cargoes built to support strategic partnerships for advancing science and developing new medicines; no specific partnership revenues currently disclosed.
Go-to-market motion3 records
Distribution channels2 records
Marketing channels6 records
nChroma Bio product offering
Product offeringCore offering
nChroma Bio develops in vivo genetic medicines by combining epigenetic editing cargoes with two proprietary targeted delivery systems—lipid nanoparticles (LNPs) for liver-specific applications and engineered virus-like particles (DLVR/eVLPs) for extrahepatic tissues. The company's pipeline includes the clinical-stage lead candidate CRMA-1001 (a liver-directed epigenetic silencer for chronic hepatitis B in Phase 1/2), PCSK9 epigenetic editors for cardiometabolic disease, and next-generation CNS-targeted epigenetic editors.
Product overview
nChroma Bio offers a single integrated platform-plus-pipeline architecture for in vivo genetic medicines, combining two core technology pillars — an Epigenetic Editing Platform for programmable gene regulation (via methylation without DNA cutting) and a modular delivery technology suite comprising lipid nanoparticles (LNPs) for liver-specific applications and DLVR Particles (engineered virus-like particles, eVLPs) for extrahepatic delivery. This integrated product engine translates directly into the named pipeline offerings: the lead clinical candidate CRMA-1001 (liver-directed epigenetic silencer delivered via LNP, in Phase 1/2 for chronic hepatitis B), the PCSK9 epigenetic editor (cardiometabolic, candidate-enabled, LNP-delivered), the PCSK9 multiplex epi/gene editing program (cardiometabolic, research), and various CNS targets (research) addressed via smaller next-generation epigenetic editors delivered through DLVR. The platform is designed disease-first — pairing potential best-in-class genetic cargoes with the appropriate delivery vehicle for the target tissue — and is offered for strategic partnership collaborations to extend across additional tissues and indications.
Differentiator
Problem solved
Functional benefit
Products and services
- CRMA-1001
- PCSK9 Epigenetic Editor Program
- PCSK9 Multiplex Program
- CNS Epigenetic Editor Program
- DLVR Delivery Platform (eVLPs)
Quantifiable outcome
- Up to 90% of treated mice achieved undetectable combined DNA and HBsAg levels with CRMA-1001 in preclinical HBV models
- +3 more outcomes
Companies that use nChroma Bio
Customer profileSegments5 records
Ideal customer profiles3 records
nChroma Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature7 records
nChroma Bio partnerships and signals
Strategic signalScale indicators8 records
Recent moves5 records
Expansion highlights6 records
nChroma Bio competitors and assessment
Company assessmentDirect peers
- Beam Therapeutics: Clinical-stage base editing company developing in vivo and ex vivo precision genetic medicines across hematology, oncology, and rare diseases. Directly comparable to nChroma in developing next-generation gene editing modalities with potential for durable, single-course treatments, although Beam's editing mechanism (base editing) differs from nChroma's epigenetic silencing.
- Prime Medicine: Clinical-stage prime editing company co-founded by David Liu (also a scientific co-founder of nChroma via Chroma Medicine). Directly comparable as a next-generation gene editing platform targeting a broad range of indications with programmable, precise genome editing without double-strand breaks.
- Verve Therapeutics: Clinical-stage in vivo gene editing company developing single-course treatments for cardiovascular disease, including an LDL cholesterol-lowering program targeting PCSK9. Directly comparable to nChroma's PCSK9 epigenetic editor and broader cardiometabolic pipeline.
- Intellia Therapeutics: Clinical-stage in vivo CRISPR/Cas9 gene editing company developing in vivo and ex vivo therapies across multiple tissues including liver and bone marrow. Comparable to nChroma as a fellow in vivo gene editing platform player, though Intellia uses DNA-cutting CRISPR while nChroma focuses on non-cutting epigenetic editing.
- Editas Medicine: Clinical-stage CRISPR/Cas9 and Cas12a gene editing company; founding CEO Kevin Bitterman is now a board member of nChroma via Atlas Venture. Directly comparable as a next-generation genetic medicines platform with overlapping scientific founders and investor syndicate.
- Arbutus Biopharma: Clinical-stage biopharmaceutical company developing a functional cure for chronic hepatitis B using RNAi (AB-729) and oral capsid inhibitor approaches. Directly competes with nChroma's CRMA-1001 in the chronic HBV functional cure space.
- Vir Biotechnology: Clinical-stage immunology company with a chronic HBV functional cure program (VIR-2218 siRNA in combination regimens with Brii Biosciences). Directly competes with nChroma in pursuing functional cure for chronic hepatitis B using oligonucleotide-based approaches.
- Aligos Therapeutics: Clinical-stage biopharmaceutical company developing therapies for chronic liver diseases including chronic hepatitis B and hepatitis D using capsid inhibitors, siRNA, and oligonucleotide approaches. Directly competes with nChroma in the chronic HBV/HDV treatment space.
Emerging players
- Korro Bio: Clinical-stage RNA editing company leveraging ADAR-mediated editing for liver and CNS indications. Comparable to nChroma as a fellow next-generation genetic medicines platform pursuing durable, single-course treatments for chronic diseases.
Broad incumbents
- Arrowhead Pharmaceuticals: Clinical-stage RNAi therapeutics company with broad pipeline including programs in HBV (ARO-HBV), cardiovascular (PCSK9), and CNS, plus multiple extrahepatic delivery platforms. Comparable to nChroma on cardiometabolic (PCSK9), HBV, and the extrahepatic delivery platform competition.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
nChroma Bio social profiles
Digital presencenChroma Bio compliance and trust
Trust signalCompliance3 records
nChroma Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
nChroma Bio leadership team
Management profileNumber of profiles
Profiles20 records
nChroma Bio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors20 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
nChroma Bio M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about nChroma Bio
What does nChroma Bio do?
nChroma Bio develops in vivo genetic medicines by combining epigenetic editing cargoes with two proprietary targeted delivery systems—lipid nanoparticles (LNPs) for liver-specific applications and engineered virus-like particles (DLVR/eVLPs) for extrahepatic tissues. The company's pipeline includes the clinical-stage lead candidate CRMA-1001 (a liver-directed epigenetic silencer for chronic hepatitis B in Phase 1/2), PCSK9 epigenetic editors for cardiometabolic disease, and next-generation CNS-targeted epigenetic editors.
Is nChroma Bio a public or private company?
nChroma Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was nChroma Bio founded?
nChroma Bio was founded in 2024. It employs 51 to 100 people.
Where is nChroma Bio based?
nChroma Bio is headquartered in Boston, United States, in the North America region.
How does nChroma Bio make money?
Two revenue lines are on record. Pre-Revenue / Clinical-Stage is the primary driver. The others are strategic Partnership Potential.
Who are nChroma Bio's main competitors?
Direct peers on record are Beam Therapeutics, Prime Medicine, Verve Therapeutics, Intellia Therapeutics, Editas Medicine, Arbutus Biopharma, Vir Biotechnology and Aligos Therapeutics. Korro Bio is listed as an emerging player. Arrowhead Pharmaceuticals is listed as a broad incumbent.
Does nChroma Bio have an API?
No public API is recorded for nChroma Bio.
What industry is nChroma Bio in?
nChroma Bio's product category is Genetic Medicines / Epigenetic Editing Therapeutics. Its primary akta.pro industry code is HLAAACAC, Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods). Its NAICS code is 541714 and its SIC code is 2836.